Endocytosis as a critical regulator of hematopoietic stem cell fate —implications for hematopoietic stem cell and gene therapy
Open Access
- 27 September 2024
- journal article
- letter
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 15 (1) , 1-4
Abstract
Hematopoietic stem cells (HSCs) have emerged as one of the most therapeutically significant adult stem cells, paving way for a range of novel curative regimens over decades. HSCs are transplanted, either directly or post restorative genetic engineering in order to repopulate a healthy hematopoietic homeostasis in patients with disorders affecting the blood and immune cells. Despite being an extensively studied system, the maintenance and expansion of functional HSCs ex vivo remains a major bottleneck. The challenge primarily stems from difficulties in reproducing HSC self-renewal divisions and gradual depletion of stemness characters, in vitro. Refining the in vitro culture can be particularly beneficial in the case of cord blood HSCs (CB-HSCs), as inadequate numbers in a single umbilical cord limits its therapeutic potential. In recent years, molecular dissection of HSC stemness has significantly improved in vitro hematopoietic stem and progenitor cells (HSPCs) culture. Despite such significant progress, lacunae exist in fully understanding all the underlying mechanisms and their interplay active in bona fide HSCs, and how it transforms when cells proliferate in culture. A new groundbreaking study titled “MYCT1 controls environmental sensing in human haematopoietic stem cells”, published in Nature in June 2024, sheds light on this complex field. Through a series of experiments, including knock-down, overexpression, single-cell RNA sequencing, and transplantation, the study identifies a previously unknown role of the MYC target 1 (MYCT1) protein in HSC maintenance. This protein acts as a crucial regulator of human HSCs, with high expression in primitive HSCs and subsequently downregulated during ex vivo culture. The study reveals that MYCT1 plays a vital role in moderating endocytosis and environmental sensing in HSCs, processes thereby essential for maintaining HSC stemness and function. This commentary will discuss the implications of the new findings for cord blood expansion in cell therapies and HSPC culture for gene therapy applications, providing valuable insights for the field of hematopoietic regenerative medicine.Keywords
Funding Information
- Wellcome Trust DBT India Alliance (IA/TSG/22/1/600431)
- Department of Biotechnology, Ministry of Science and Technology, India (BT/PR31616/MED/31/408/2019, BT/PR45683/MED/31/465/2022, BT/PR38267/GET/119/348/2020)
This publication has 14 references indexed in Scilit:
- MYCT1 controls environmental sensing in human haematopoietic stem cellsNature, 2024
- CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-ThalassemiaNew England Journal of Medicine, 2021
- Haematopoietic stem cell self-renewal in vivo and ex vivoNature Reviews Genetics, 2020
- Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1–2 safety and feasibility studyThe Lancet Haematology, 2020
- MLLT3 governs human haematopoietic stem-cell self-renewal and engraftmentNature, 2019
- Integrin-α3 Is a Functional Marker of Ex Vivo Expanded Human Long-Term Hematopoietic Stem CellsCell Reports, 2019
- Engineering a haematopoietic stem cell niche by revitalizing mesenchymal stromal cellsNature Cell Biology, 2019
- EPCR expression marks UM171-expanded CD34+ cord blood stem cellsBlood, 2017
- Concise Review: Ex Vivo Expansion of Cord Blood-Derived Hematopoietic Stem and Progenitor Cells: Basic Principles, Experimental Approaches, and Impact in Regenerative MedicineStem Cells Translational Medicine, 2013
- Aryl Hydrocarbon Receptor Antagonists Promote the Expansion of Human Hematopoietic Stem CellsScience, 2010